Insmed (INSM) Is Down 10.5% After Halting Brensocatib in HS Trial Miss - What's Changed

Simply Wall St.04-17

Insmed Incorporated recently reported that its Phase 2b CEDAR trial of brensocatib in adults with moderate to severe hidradenitis suppurativa failed to meet primary and secondary efficacy endpoints, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2628747274?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-04-17 17:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2628747274","market":"sg","top_or_hot":-1,"title":"Insmed (INSM) Is Down 10.5% After Halting Brensocatib in HS Trial Miss - What's Changed","media":"Simply Wall St.","content":"<div>\n<p>Insmed Incorporated recently reported that its Phase 2b CEDAR trial of brensocatib in adults with moderate to severe hidradenitis suppurativa failed to meet primary and secondary efficacy endpoints, ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-insm/insmed/news/insmed-insm-is-down-105-after-halting-brensocatib-in-hs-tria\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insmed (INSM) Is Down 10.5% After Halting Brensocatib in HS Trial Miss - What's Changed</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsmed (INSM) Is Down 10.5% After Halting Brensocatib in HS Trial Miss - What's Changed\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-17 17:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-insm/insmed/news/insmed-insm-is-down-105-after-halting-brensocatib-in-hs-tria><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Insmed Incorporated recently reported that its Phase 2b CEDAR trial of brensocatib in adults with moderate to severe hidradenitis suppurativa failed to meet primary and secondary efficacy endpoints, ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-insm/insmed/news/insmed-insm-is-down-105-after-halting-brensocatib-in-hs-tria\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4528","symbol_name":"SaaS概念","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-insm/insmed/news/insmed-insm-is-down-105-after-halting-brensocatib-in-hs-tria","article_id":"2628747274","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-insm/insmed/news/insmed-insm-is-down-105-after-halting-brensocatib-in-hs-tria","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2628747274","pubTimestamp":1776416786,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Insmed Incorporated recently reported that its Phase 2b CEDAR trial of brensocatib in adults with moderate to severe hidradenitis suppurativa failed to meet primary and secondary efficacy endpoints, leading the company to halt development of the drug for this indication despite a clean safety profile.\nAn interesting aspect of the CEDAR data is that patients on placebo showed a greater reduction in abscess and inflammatory nodule counts than those on either brensocatib dose, raising questions...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4528":"SaaS概念","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4588":"碎股","ARTY":"ISHARES FUTURE AI & TECH ETF","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","BK4551":"寇图资本持仓","AGIX":"通用人工智能 ETF-AGIX","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4023":"应用软件","BK4543":"AI","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4587":"ChatGPT概念","BK4585":"ETF&股票定投概念","AI":"C3.ai, Inc.","INSM":"Insmed","BK4139":"生物科技","AIYY":"YIELDMAX AI OPTION INCOME STRATEGY ETF","AIPO":"Defiance AI and Power Infrastructure ETF","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF"},"translate_title":"Insmed(INSM)因HS试验失败而停止Brensocatib后股价下跌10.5%-发生了什么变化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AIYY":0.6,"AIPO":0.74,"ARTY":0.63,"AI":0.63,"INSM":1.5,"CHAT":0.63,"AGIX":0.63},"content_text":"Insmed Incorporated recently reported that its Phase 2b CEDAR trial of brensocatib in adults with moderate to severe hidradenitis suppurativa failed to meet primary and secondary efficacy endpoints, leading the company to halt development of the drug for this indication despite a clean safety profile. An interesting aspect of the CEDAR data is that patients on placebo showed a greater reduction in abscess and inflammatory nodule counts than those on either brensocatib dose, raising questions about trial design, disease variability and future development priorities for the asset. We will now examine how discontinuing brensocatib in hidradenitis suppurativa may influence Insmed’s broader brensocatib-centered investment narrative and expectations. Find 58 companies with promising cash flow potential yet trading below their fair value.AdvertisementInsmed Investment Narrative RecapTo own Insmed, you need to believe that brensocatib in bronchiectasis and ARIKAYCE expansion can offset current losses and justify today’s valuation. The CEDAR setback in hidradenitis suppurativa appears immaterial to the near term brensocatib bronchiectasis launch catalyst, but it does highlight development risk around broader brensocatib indications. In that context, the recent positive Phase 3b ENCORE results for ARIKAYCE, supporting a potential label expansion with an sNDA planned for H2 2026, stand out as especially relevant, as they reinforce Insmed’s respiratory focus while brensocatib’s HS program is discontinued. Yet, while the HS decision may not change the headline catalyst, it underscores a risk investors should be aware of around... Read the full narrative on Insmed (it's free!)Insmed's narrative projects $3.9 billion revenue and $952.9 million earnings by 2029.Uncover how Insmed's forecasts yield a $214.32 fair value, a 50% upside to its current price.Exploring Other PerspectivesINSM 1-Year Stock Price Chart Four fair value estimates from the Simply Wall St Community span from US$212.50 to US$21,337.07, underlining just how far apart individual views can be. Against that backdrop, the key upcoming catalyst remains the expected U.S. brensocatib bronchiectasis launch, which could be pivotal for how the business ultimately scales.Explore 4 other fair value estimates on Insmed - why the stock might be worth just $212.50!Form Your Own VerdictDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Insmed research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.Our free Insmed research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Insmed's overall financial health at a glance.Seeking Other Investments?Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2628747274","isCrawlerRequest":true}